J&J Strengthens U.S. Pharma Supply Chain with Two Next-Gen Facilities
The company is making moves to strengthen its pharmaceutical supply chain, boost resilience, and support advanced manufacturing capabilities.
This story is courtesy of our content partner, Thomasnet.com
Johnson & Johnson plans to construct two new production facilities in the U.S. as part of a broader strategy to localize the manufacturing of advanced medicines. These sites are part of a $55 billion commitment to domestic research, development, and technology through 2029.
Expanding the East Coast Footprint
The pharmaceutical and biotechnology company is establishing a next-generation cell therapy production site in Pennsylvania and a biologics plant in North Carolina.
J&J added that these additions complement an existing $2 billion biologics plant currently under construction in Wilson, North Carolina, which is expected to generate roughly 5,000 jobs. The organization has also recently acquired a 160,000-square-foot biopharmaceutical facility in Holly Springs to bolster its long-term production capabilities.
Strategic Pricing and Access
In coordination with federal initiatives, the healthcare firm is launching a direct-to-patient platform that aims to provide pharmaceutical products at discounted rates. According to the manufacturer, this move seeks to align domestic drug pricing more closely with costs found in other developed international markets.
The agreement also provides the company with specific exemptions from certain tariffs.
Future Infrastructure Goals
The organization aims to produce the majority of its complex therapies within the U.S. to ensure more reliable patient access, according to the company announcement. By investing heavily in advanced manufacturing technologies, the firm is transitioning away from older production models to more efficient, automated systems.
J&J added that more announcements regarding domestic production are expected before the end of the year.
Image credit: Formatoriginal/Shutterstock